MIRA SAFETY FULL
MIRA SAFETY REGISTRATION

Comes with a pre-installed hydration system and canteen (drinking system variant only).

Fits up to 2 standard 40-mm 1/7” NATO filter cartridges (widely available with varying protection levels).

Tested resistance to mustard gas penetration for nearly 30 hours.

Hypoallergenic inner mask prevents fogging, even under hard use.

Full-face panoramic design with a large visor to enable a wide-angle view.

Durable bromobutyl rubber construction (meets CBRN protection standards).Trusted by police worldwide and government entities in the Czech Republic, Norway, Portugal, Chile, Saudi Arabia, Turkey, Kuwait, Latvia and Lebanon.Uses widely available NATO-standard, 40-mm filter cartridges.Compatible with the 3M Safety 6878 Spectacle Kit (sold separately).Key Features of the CM-6M Tactical Gas Mask:

MIRA SAFETY FULL

The Company announced in March the completion of enrollment in the ZETA-1 Phase 2b clinical trial of APX3330 to treat DR/DME.Combining premium features with superior mil-spec construction, MIRA Safety’s CM-6M CBRN tactical gas mask / full-face respirator protects your face, internal organs and respiratory system against a full spectrum of toxic industrial chemicals (TIC) and chemical warfare agents (CWA) including chemical, biological and nuclear threats such as radioactive dust, noxious gas, vaporized pollutants and more. Ocuphire’s second product candidate, APX3330, is an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME) and has been studied in 11 Phase 1 and 2 trials. The Company recently reported positive topline results from LYNX-1 Phase 3 trial of Nyxol for NVD. Ocuphire also reported positive topline data from the VEGA-1 Phase 2 trial of Nyxol for treatment of presbyopia, both Nyxol as a single agent and Nyxol with low dose pilocarpine (“LDP”) 0.4% as adjunctive therapy.

MIRA SAFETY REGISTRATION

Ocuphire has reported positive data from MIRA-2 and MIRA-3 registration trials and MIRA-4 pediatric safety trial for the treatment of RM. The Company’s lead product candidate, Nyxol ® eye drops (0.75% phentolamine ophthalmic solution), is a once-daily, preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including reversal of pharmacologically-induced mydriasis (RM), presbyopia and dim light or night vision disturbances (NVD), and has been studied in 12 completed clinical trials. Ocuphire is a publicly-traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of refractive and retinal eye disorders. For more details, please see the Investors and Events section of Ocuphire’s corporate website. If you are interested in arranging a 1x1 meeting request, please contact your bank/conference representative or. Wednesday, August 17, 2022, available after 7 AM EST

Ocuphire Pharma (OCUP) Company Presentation Zaina Al-Mohtaseb, MD and Selina McGee, OD, FAAO Mina Sooch, MBA, CEO and Founder, Ocuphire Panel Discussion: Front of the Eye Progress and Flying Under the Radar - A Fireside With OCUP Wainwright 2nd Annual Ophthalmology Virtual Conference – August 17, 2022 of Business Development and Market Strategy

Wednesday, August 10, 2022, 2:00 PM – 2:20 PM EDTĬharlie Hoffmann, VP of Corporate Development and Operations Canaccord Genuity 42nd Annual Growth Conference – August 8-11, 2022įireside Chat with Ocuphire Pharma (OCUP) Wainwright analyst, Matthew Caufield, MBA, MS, on Wednesday, August 17, 2022. Wainwright 2 nd Annual Ophthalmology Virtual Conference being held Augand participate in a fireside discussion featuring Ocuphire with 2 leading ophthalmology and optometry KOLs hosted by H.C. Second, Mina Sooch Founder and CEO will present at the H.C. First, Charlie Hoffmann, VP of Corporate Development and Operations, and Ronil Patel, Senior Director of Business Development and Market Strategy will participate in a fireside chat hosted by John Newman, PhD, CFA at the Canaccord Genuity 42 nd Annual Growth Conference on August 10, 2022. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced presentations at two healthcare banking conferences.

08, 2022 (GLOBE NEWSWIRE) - Ocuphire Pharma, Inc. Wainwright 2 nd Annual Ophthalmology Virtual Conference on August 17, 2022, including a Fireside Panel with OCUP “Front of the Eye Progress and Flying Under the Radar”įARMINGTON HILLS, Mich., Aug. Canaccord Genuity 42 nd Annual Growth Conference on August 10, 2022

Mira safety